NR1H4 and lung disorder: FXR agonists like 6-ethyl chenodeoxycholic acid (OCA) have shown anti-inflammatory and anti-fibrotic effects in lung tissues, making FXR a potential target for treating certain lung diseases (Wu et al., 2020).